Merrimack Pharm (MACK) Reports Q3 Loss of $1.81

Merrimack Pharm (NASDAQ: MACK) reported Q3 EPS of ($1.81), versus ($0.25) reported last year. Revenue for the quarter came in at $11.3 million, versus $8.6 million reported last year.

For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing